<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Flunisolide (nasal): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Flunisolide (nasal): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Flunisolide (nasal): Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9125" href="/d/html/9125.html" rel="external">see "Flunisolide (nasal): Drug information"</a> and <a class="drug drug_patient" data-topicid="11680" href="/d/html/11680.html" rel="external">see "Flunisolide (nasal): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F10482306"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Corticosteroid, Intranasal</span></li></ul></div>
<div class="block dop drugH1Div" id="F8097263"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa4ba73f-002d-4f3f-b47c-e13805dd7d36">Rhinitis, perennial or seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinitis, perennial or s</b>
<b>easonal:</b> Intranasal (25 mcg/spray):</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents ≤14 years: Initial: 1 spray (25 mcg) <b>per nostril</b> 3 times daily <b>or </b>2 sprays (50 mcg) <b>per nostril</b> twice daily (total daily dose: 150 to 200 mcg/day); maximum daily dose: 4 sprays <b>per nostril/day</b> (200 mcg/<b>day</b>); once symptoms are controlled, the dose should be reduced to the lowest effective dose; 1 spray (25 mcg) <b>per nostril</b> once daily may be effective in some patients (total daily dose: 50 mcg/day)</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥15 years: Initial: 2 sprays (50 mcg) <b>per nostril</b> twice daily (total daily dose: 200 mcg/day); if needed, may increase to 2 sprays (50 mcg) <b>per nostril</b> 3 times daily (total daily dose: 300 mcg/day); maximum daily dose: 8 sprays <b>per nostril/day</b> (400 mcg/<b>day</b>); once symptoms are controlled, the dose should be reduced to the lowest effective dose; 1 spray (25 mcg) <b>per nostril</b> once daily may be effective in some patients (total daily dose: 50 mcg/day)</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51110628"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51110629"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F8097264"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9125" href="/d/html/9125.html" rel="external">see "Flunisolide (nasal): Drug information"</a>)</p>
<p style="text-indent:0em;">
<b>Note:</b> For patients with mucous crusting, rinsing with saline nasal spray before flunisolide administration can remove mucous crusting and improve nasal coating (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-deShazo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-deShazo.1'])">Ref</a></span>). If nasal obstruction is so severe that sprays cannot penetrate, consider concomitant use of an intranasal decongestant for up to 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ed30d02d-dd05-494e-bc5b-0d0387493686">Allergic rhinitis, perennial or seasonal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Allergic rhinitis, perennial or seasonal:</b>
<b>Intranasal:</b> 2 sprays (50 mcg) in each nostril twice daily (total daily dose: 200 mcg/day); may increase to 2 sprays in each nostril 3 times daily (total daily dose: 300 mcg/day); maximum dose: 8 sprays/day in each nostril (total daily dose: 400 mcg/day).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1820e284-41e2-4255-93fb-309e4d01aef5">Nonallergic rhinitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonallergic rhinitis (off label): Intranasal:</b> 2 sprays (50 mcg) in each nostril twice daily (total daily dose: 200 mcg/day); may increase to 2 sprays in each nostril 3 times daily (total daily dose: 300 mcg/day); maximum dose: 8 sprays/day in each nostril (total daily dose: 400 mcg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lieberman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lieberman.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992131"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989360"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F8097216"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Burning sensation of the nose (≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion (15%), stinging sensation of the nose (≤13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Anosmia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry nose, nasal mucosa irritation, rhinitis, sneezing</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Nasal mucosa ulcer</p></div>
<div class="block coi drugH1Div" id="F8097185"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to flunisolide or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F8097186"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Pediatric patients may be more susceptible to systemic toxicity. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving ≥20 mg per day of prednisone (or equivalent) may be most susceptible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed wound healing: Avoid use in patients with recent nasal septal ulcers, nasal surgery or nasal trauma until healing has occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox and/or measles should be avoided, especially if not immunized; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intramuscular immunoglobulin, respectively, may be indicated; if chickenpox develops, treatment with antiviral agents may be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Local nasal effects: Nasal septal perforation, nasal ulceration, epistaxis, and localized <i>Candida albicans</i> infections of the nose and/or pharynx may occur. Monitor patients periodically for adverse nasal effects; discontinuation of therapy may be necessary if an infection occurs. If nasal effects occur, use with caution until area is healed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Avoid using higher than recommended dosages; suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, or hypercortisolism (Cushing's syndrome) may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients, even at recommended doses via intranasal route (monitor growth).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for use in the presence of untreated localized infections involving the nasal mucosa. Do not use for longer than 3 weeks if no clinical signs of improvement. Avoid excessive doses; systemic effects may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Symptoms of corticosteroid withdrawal (eg, joint pain, muscle pain, lassitude, depression) may occur when transferring from a systemic corticosteroid to a topical corticosteroid.</p></div>
<div class="block foc drugH1Div" id="F8097304"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mcg/actuation (0.025%) (25 mL)</p></div>
<div class="block geq drugH1Div" id="F8097135"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F8097306"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Flunisolide Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 MCG/ACT (0.025%) (per mL): $2.55 - $2.88</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53569952"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">When used short term as adjunctive therapy in acute bacterial rhinosinusitis (ABRS), intranasal steroids show modest symptomatic improvement and few adverse effects; improvement is primarily due to increased sinus drainage. Use should be considered optional in ABRS; however, intranasal corticosteroids should be routinely prescribed to ABRS patients who have a history of or concurrent allergic rhinitis (Chow 2012).</p></div>
<div class="block admp drugH1Div" id="F52614346"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For intranasal use only. Shake well prior to each use. Before first use, prime by pressing pump 5 to 6 times or until a fine spray appears. Repeat priming if ≥5 days between use or if dissembled for cleaning. Administer at regular intervals. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright, and close off the other nostril. Breathe in through nose. While inhaling, press pump to release spray. Do not spray into eyes. Discard after labeled number of doses has been used, even if bottle is not completely empty.</p></div>
<div class="block adm drugH1Div" id="F8097287"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intranasal:</b> For use in nostril only; do not spray in eyes or mouth. Before first use, prime by pressing pump 5 to 6 times or until a fine spray appears. Repeat priming if ≥5 days between use, or if dissembled for cleaning. Administer at regular intervals. Blow nose to clear nostrils. Insert applicator into nostril, keeping bottle upright and head bent forward, and close off the other nostril. Do not spray directly into septum. Breathe in through nose. While inhaling, press pump to release spray.</p></div>
<div class="block sts drugH1Div" id="F8097228"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Store at 15°C to 25°C (59°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53570517"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Management of nasal symptoms associated with seasonal or perennial rhinitis (FDA approved in ages ≥6 years and adults)</p>
<p style="text-indent:0em;margin-top:2em;">Intranasal corticosteroids have also been used as an adjunct to antibiotics in empiric treatment of acute bacterial rhinosinusitis primarily in patients with history of allergic rhinitis (Chow 2012) and in pediatric patients with mild obstructive sleep apnea syndrome who cannot undergo adenotonsillectomy or who still have symptoms after surgery (Marcus 2012).</p></div>
<div class="block mst drugH1Div" id="F8097076"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Flunisolide may be confused with Flumadine, fluocinonide.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299346"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F8097223"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: Corticosteroids (Nasal) may diminish the therapeutic effect of Esketamine.  Management: Patients who require a nasal corticosteroid on an esketamine dosing day should administer the nasal corticosteroid at least 1 hour before esketamine.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F8097163"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">An agent with less systemic absorption is preferred for the treatment of allergic rhinitis during pregnancy (BSACI [Scadding 2017]).</p></div>
<div class="block mopp drugH1Div" id="F53570518"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mucous membranes for signs of fungal infection, growth (pediatric patients), signs/symptoms of HPA axis suppression/adrenal insufficiency; ocular changes </p></div>
<div class="block pha drugH1Div" id="F8097229"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; does not depress hypothalamus</p></div>
<div class="block phk drugH1Div" id="F8097255"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: ~50%</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23671217"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Syntaris</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Syntaris</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Syntaris</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Syntaris</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lokilan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nasalide</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Syntaris | Syntaris hayfever</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Syntaris</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Syntaris</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Syntaris</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Flunisolide Alfrapharma | Gibiflu | Lunis | Multinebulgen | Syntaris | Ventoflu</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Rohto alguard clear nose | Synaclyn</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Syntaris-nasal</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Syntaris | Syntharis</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lokilan | Syntaris</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Tarisin | Valoflu</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Syntaris</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nasalide | Nasarel</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Lokilan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Nasalide</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al, “IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,” <i>Clin Infect Dis</i>, 2012, 54(8):e72-112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flunisolide-nasal-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-deShazo.1">
<a name="deShazo.1"></a>deShazo RD, Kemp SF. Pharmacotherapy of allergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 28, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol.</i> 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flunisolide-nasal-pediatric-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Flunisolide nasal solution [prescribing information]. Bridgewater, NJ: Bausch + Lomb Inc; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26012297">
<a name="26012297"></a>Guo L, Sun X, Yang J, et al. Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis. <i>J Otolaryngol Head Neck Surg.</i> 2015;29(3):243-245, 251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flunisolide-nasal-pediatric-drug-information/abstract-text/26012297/pubmed" id="26012297" target="_blank">26012297</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lieberman.1">
<a name="Lieberman.1"></a>Lieberman PL. Chronic nonallergic rhinitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22926173">
<a name="22926173"></a>Marcus CL, Brooks LJ, Draper KA, et al, "Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome," <i>Pediatrics</i>, 2012, 130(3):576-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flunisolide-nasal-pediatric-drug-information/abstract-text/22926173/pubmed" id="22926173" target="_blank">22926173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8258615">
<a name="8258615"></a>Meltzer EO, Orgel HA, Backhaus JW, et al. Intranasal flunisolide spray as an adjunct to oral antibiotic therapy for sinusitis. <i>J Allergy Clin Immunol</i>. 1993;92(6):812-823.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flunisolide-nasal-pediatric-drug-information/abstract-text/8258615/pubmed" id="8258615" target="_blank">8258615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24654314">
<a name="24654314"></a>Price D, Shah S, Bhatia S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis. <i>J Investig Allergol Clin Immunol</i>. 2013;23(7):495-503.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flunisolide-nasal-pediatric-drug-information/abstract-text/24654314/pubmed" id="24654314" target="_blank">24654314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg</i>. 2015;152(2 suppl):S1-S39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flunisolide-nasal-pediatric-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30239057">
<a name="30239057"></a>Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (revised edition 2017; first edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856-889. doi:10.1111/cea.12953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flunisolide-nasal-pediatric-drug-information/abstract-text/30239057/pubmed" id="30239057" target="_blank">30239057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21658314">
<a name="21658314"></a>Varricchio A, Capasso M, De Lucia A, et al. Intranasal flunisolide treatment in patients with non-allergic rhinitis. <i>Int J Immunopathol Pharmacol</i>. 2011;24(2):401-409.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flunisolide-nasal-pediatric-drug-information/abstract-text/21658314/pubmed" id="21658314" target="_blank">21658314</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 15984 Version 142.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
